Johnson & Johnson's most recent trend suggests a bearish bias. One trading opportunity on Johnson & Johnson is a Bear Call Spread using a strike $132.00 short call and a strike $137.00 long call offers a potential 44.51% return on risk over the next 14 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $132.00 by expiration. The full premium credit of $1.54 would be kept by the premium seller. The risk of $3.46 would be incurred if the stock rose above the $137.00 long call strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Johnson & Johnson is bearish.
The RSI indicator is at 26.08 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Johnson & Johnson
Oklahoma makes final bid to hold J&J responsible for opioid epidemic
Wed, 31 Jul 2019 22:38:09 +0000
REFILE-Oklahoma makes final bid to hold J&J responsible for opioid epidemic
Wed, 31 Jul 2019 22:35:28 +0000
Oklahoma's attorney general on Wednesday made his final bid to force Johnson & Johnson to pay $17 billion for its part in fueling the opioid epidemic, saying the drugmaker's “egregious” marketing caused an oversupply of addictive drugs and overdose deaths. Opioids were involved in almost 400,000 overdose deaths from 1999 to 2017, according to the U.S. Centers for Disease Control and Prevention.
Why Pfizer Stock Continues to Tank after Mylan Deal
Wed, 31 Jul 2019 19:23:46 +0000
Pfizer stock (PFE) has fallen 10% in the past two days on its deal with Mylan (MYL) and its lower earnings guidance.
Veracyte (VCYT) Q2 2019 Earnings Call Transcript
Wed, 31 Jul 2019 05:24:21 +0000
VCYT earnings call for the period ending June 30, 2019.
Merck Shares Rise on Strong Sales Growth
Tue, 30 Jul 2019 17:14:27 +0000
Drugmaker revises revenue, earnings guidance Continue reading…
Also on Market Tamer…
Follow Us on Facebook